Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression

Rosiglitazone reduces diabetes angiopathy by inhibiting mitochondrial dysfunction dependent on regulating HSP22 expression

Summary: The effects of rosiglitazone (RSG) in patients with type 2 diabetes mellitus (T2DM) remain controversial. Here, we first used network pharmacology to identify the common targets of RSG in the treatment of diabetes angiopathy (DA). Enrichment analysis found that the common genes were involve...

Full description

Bibliographic Details
Main Authors: Lingling Yu, Shengsong Chen, Qian Liang, Chahua Huang, Weifang Zhang, Longlong Hu, Yun Yu, Liang Liu, Xiaoshu Cheng, Huihui Bao
Format: Article
Language:English
Published: Elsevier 2023-04-01
Series:iScience
Subjects:
Drugs
Human metabolism
Online Access:http://www.sciencedirect.com/science/article/pii/S2589004223002717

Internet

http://www.sciencedirect.com/science/article/pii/S2589004223002717

Similar Items